UBL Pakistan Enterprise ETF
Price
Rs39.88
YTD
+18.50%
Expense
1.50%
Yield
2.43%
EDEN
EDEN NYSE
iShares MSCI Denmark ETF · by BlackRock
Price
kr118.49
YTD return
+8.50%
1Y return
12.80%
Expense ratio
0.53%
Dividend yield
1.20%
AUM
$180M
EDEN provides exposure to Danish equities, dominated by Novo Nordisk, the world's largest pharmaceutical company by market cap. Denmark's market offers high-quality healthcare and industrial exposure.
EDEN: Denmark's Quality Champions
The iShares MSCI Denmark ETF provides access to one of Europe's best-performing equity markets. Denmark's market is dominated by globally competitive companies in healthcare (Novo Nordisk, Coloplast), industrials (Vestas, DSV), and consumer goods (Carlsberg).
Novo Nordisk Effect
Novo Nordisk, maker of the blockbuster GLP-1 drugs Ozempic and Wegovy, typically represents 30-40% of EDEN's portfolio. The obesity treatment revolution has made Novo Nordisk the most valuable company in Europe and a significant driver of Danish market returns.
Wind Energy Leadership
Denmark is a pioneer in wind energy, home to Vestas (world's largest wind turbine manufacturer) and Ørsted (largest offshore wind developer). These companies provide exposure to the global renewable energy transition.
Top holdings
Every holding links to its own page with a live price and the full list of funds that own it.
| # | Holding | Ticker | Sector | Weight | Price |
|---|---|---|---|---|---|
| 1 | Novo Nordisk | NVO | Healthcare | 35.50% | $46.26 -1.97% |
| 2 | DSV A/S | DSV | Industrials | 8.20% | 1,351.50 -3.46% |
| 3 | Vestas Wind Systems | VWDRY | Industrials | 5.80% | $11.22 4.57% |
| 4 | Coloplast | CLPBY | Healthcare | 4.50% | $7.13 -0.14% |
| 5 | Carlsberg | CABGY | Consumer Staples | 3.80% | $27.43 -0.87% |
Frequently asked questions
Why is Novo Nordisk so dominant in EDEN?
Novo Nordisk represents approximately 35% of the Danish equity market by cap. Its GLP-1 diabetes and obesity drugs have driven extraordinary growth, making it Europe's most valuable company.
Is EDEN too concentrated?
Yes, EDEN's heavy Novo Nordisk concentration creates single-stock risk. Investors should consider this when sizing their allocation.
Compare with similar ETFs
iShares MSCI Norway ETF
Price
kr36.65
YTD
+3.50%
Expense
0.53%
Yield
3.80%
Franklin FTSE Sweden ETF
Price
kr29.50
YTD
+4.20%
Expense
0.09%
Yield
3.20%
KraneShares MSCI Saudi Arabia ETF
Price
SR22.80
YTD
+2.80%
Expense
0.69%
Yield
2.50%
Meezan Pakistan ETF
Price
Rs18.81
YTD
+12.50%
Expense
1.50%
Yield
11.19%
KraneShares MSCI All Korea 20/35 Index ETF
Price
₩28.50
YTD
+5.20%
Expense
0.59%
Yield
1.80%
Community
EDEN discussion
Questions on fair value, cost, dividends and risk — answered with the fund data on this page.
What is the fair value of EDEN in 2026?
EDEN price prediction 2026: what actually drives it?
Does EDEN pay a dividend, and how reliable is the yield?
Is EDEN a good long-term hold, or too concentrated?
Ask a question about EDEN
Questions are reviewed before publishing. Please do not ask for personal investment advice — we cannot provide it.